Publications

The methyltransferases METTL7A and METTL7B confer resistance to thiol-based histone deacetylase inhibitors. Robey RW, Fitzsimmons CM, Guiblet WM, Frye WJE, González Dalmasy JM, Wang L, Russell DA, Huff LM, Perciaccante AJ, Ali-Rahmani F, Lipsey CC, Wade HM, Mitchell AV, Maligireddy SS, Terrero D, Butcher D, Edmondson EF, Jenkins LM, Nikitina T, Zhurkin VB, Tiwari AK, Piscopio AD, Totah RA, Bates SE, Arda HE, Gottesman MM, Batista PJ. Mol Cancer Ther. 2023 Dec 28. doi: 10.1158/1535-7163.MCT-23-0144. Online ahead of print. PMID: 38151817
High-throughput cytochrome P450 loss and metabolic intermediate complex assays to aid in designing out of CYP3A inactivation. Russell DA, Cerny MA. Methods Enzymol. 2023;690:341-368. doi: 10.1016/bs.mie.2023.08.002. Epub 2023 Sep 9. PMID: 37858534

METTL7A (TMT1A) and METTL7B (TMT1B) are responsible for alkyl S-thiol methyl transferase activity in liver. Russell DA, Chau MK, Shi Y, Levasseur IN, Maldonato BJ, Totah RA. Drug Metab Dispos. 2023 May 3:DMD-AR-2023-001268. doi: 10.1124/dmd.123.001268. Online ahead of print.

Human METTL7B is an alkyl thiol methyltransferase that metabolizes hydrogen sulfide and captopril. Maldonato BJ, Russell DA, Totah RA. Sci Rep. 2021 Mar 1;11(1):4857. doi: 10.1038/s41598-021-84218-5. PMID: 33649426